ethyl 3-bromo-6-methoxy-1-naphthoate | 255051-67-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: ethyl 3-bromo-6-methoxy-1-naphthoate
• 英文别名: ethyl 3-bromo-6-methoxynaphthalene-1-carboxylate
• CAS: 255051-67-3
• 化学式: C₁₄H₁₃BrO₃
• 分子量: 309.159
• InChiKey: KYBRCVZCDKFZCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-bromo-6-methoxy-1-naphthoate 在 四(三苯基膦)钯 草酰氯 、 吡啶盐酸盐 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 methyl 3-cyano-6-hydroxy-1-naphthoate
  参考文献：
  名称：

  Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity

  摘要：

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

  DOI：

  10.1021/jm020094i
• 作为产物：
  描述：

  (2Z,4Z)-4-Bromo-2-ethoxy-5-(3-methoxy-phenyl)-penta-2,4-dienoic acid ethyl ester 在 碘 、 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 1.0h， 生成 ethyl 3-bromo-6-methoxy-1-naphthoate
  参考文献：
  名称：

  环中含有其他取代基的托勒司他类似物的合成及其作为醛糖还原酶抑制剂的评估。鉴定有效的口服活性2-氟衍生物。

  摘要：

  制备了一系列醛糖还原酶抑制剂，它们与有效的口服活性抑制剂托瑞司他（1）类似。这些化合物（5、7、9和10）在1的萘环的一个未占用位置上具有一个额外的取代基。分别来自5和7系列的几个成员的伯酰胺前药分别是6和8。也准备好了。在两个体外系统中对这些化合物进行了评估：从牛晶状体分离的酶制剂以评估其内在的抑制活性，在坐骨神经测定法中进行分离以测定其穿透神经组织膜的能力。还对这些化合物作为半乳糖醇在半乳糖喂养大鼠的晶状体，坐骨神经和隔膜中蓄积的抑制剂进行了体内评估。通常，系列5、7、9中的化合物 和10种是牛晶状体醛糖还原酶的有效抑制剂。来自系列5、7和9的2-卤代类似物在用4天半乳糖喂养的大鼠的神经中表现出高活性，在某些情况下，伯酰胺前药8增强了各自的体内效力羧酸7.两种2-氟衍生物8a和9a在体内具有特别高的活性，因此被选择用于其他研究。在这些试验中，通过它们的ED50判断，发现这些化合物与半乳

  DOI：

  10.1021/jm00112a029

文献信息

• [EN] N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS<br/>[FR] NAPHTALENE CARBOXAMIDES N-SUBSTITUES EN TANT QU'ANTAGONISTES DE RECEPTEURS DES NEUROKININES
  申请人：ZENECA LTD

  公开号：WO2000002859A1

  公开（公告）日：2000-01-20

  A compound of formula (I) wherein: R is alkyl; R1 is optionally substituted phenyl, 2-oxo-tetrahydro-1(2H)-pyrimidinyl, or 2-oxo-1-piperidinyl; R2 is hydrogen, alkoxy, alkanoyloxy, alkoxycarbonyl, alkanoylamino, acyl, alkyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl where the alkyl groups are the same or different, hydroxy, thioacyl, thiocarbamoyl, N-alkylthiocarbamoyl, or N,N-dialkylthiocarbamoyl where the alkyl groups are the same or different. X¿1? and X2 are independently hydrogen or halo, provided that at least one of X1 or X2 is halo; and R?3, R4, R5, and R6¿ are independently hydrogen, cyano, nitro, trifluoromethoxy, trifluoromethyl, or alkylsulfonyl are antagonists of at least one tachykinin receptor and are useful in the treatment of depression, anxiety, asthma, pain, inflammation, urinary incontinence and other disease conditions. Processes for their preparation are described, as are compositions containing them and their use.

  化合物的化学式(I)，其中：R为烷基; R1为可选取代的苯基，2-氧代-四氢-1(2H)-嘧啶基或2-氧代-1-哌啶基; R2为氢、烷氧基、烷酰氧基、烷氧羰基、烷酰胺、烷基、氨基甲酰、N-烷基氨基甲酰、N,N-二烷基氨基甲酰，其中烷基团相同或不同，羟基、硫代酰基、硫代氨基、N-烷基硫代氨基、N,N-二烷基硫代氨基，其中烷基团相同或不同。X1和X2独立地为氢或卤素，但至少其中之一为卤素; R3、R4、R5和R6独立地为氢、氰基、硝基、三氟甲氧基、三氟甲基或烷基磺酰基，是至少一种快速激动肽受体的拮抗剂，可用于治疗抑郁症、焦虑症、哮喘、疼痛、炎症、尿失禁和其他疾病。描述了它们的制备过程，以及包含它们和它们的使用的组合物。
• N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
  申请人：Astra Zeneca AB

  公开号：US06365602B1

  公开（公告）日：2002-04-02

  A compound of formula I wherein: R is alkyl; R1 is optionally substituted phenyl 2-oxo-tetrahydro-1(2H)-pyrimidinyl, or 2-oxo-1-piperidinyl; R2 is hydrogen, alkoxy, alkanoyloxy, alkoxycarbonyl, alkanoylamino, acyl, alkyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl where the alkyl groups are the same or different, hydroxy, thioacyl, thiocarbamoyl, N-alkylthiocarbamoyl, or N,N-dialkylthiocarbamoyl where the alkyl groups are the same or different. X1 and X2 are independently hydrogen or halo, provided that at least one of X1 or X2 is halo; and R3, R4, R5 and R6 are independently hydrogen, cyano, nitro, trifluoromethoxy, trifluoromethyl, or alkylsulfonyl are antagonists of at least one tachykinin receptor and are useful in the treatment of depression, anxiety, asthma, pain, inflammation, urinary incontinence and other disease conditions. Process for their preparation are described, as are compositions containing them and their use.

  化合物I的化学式为：其中R为烷基；R1为可选取代的苯基2-氧代四氢-1（2H）-嘧啶基，或2-氧代-1-哌啶基；R2为氢、烷氧基、烷酰氧基、烷氧羰基、烷酰胺基、酰基、烷基、氨基甲酰、N-烷基氨基甲酰、N,N-二烷基氨基甲酰（其中烷基可以相同或不同）、羟基、硫代酰基、硫代氨基甲酰、N-烷基硫代氨基甲酰或N,N-二烷基硫代氨基甲酰（其中烷基可以相同或不同）。X1和X2独立地为氢或卤素，但至少其中之一为卤素；R3、R4、R5和R6独立地为氢、氰基、硝基、三氟甲氧基、三氟甲基或烷基磺酰基，是至少一种速激肽受体的拮抗剂，可用于治疗抑郁症、焦虑症、哮喘、疼痛、炎症、尿失禁和其他疾病。描述了它们的制备过程，以及含有它们的组合物和它们的用途。
• N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS
  申请人：AstraZeneca AB

  公开号：EP1097137A1

  公开（公告）日：2001-05-09
• US6365602B1
  申请人：——

  公开号：US6365602B1

  公开（公告）日：2002-04-02
• Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity
  作者：Jeffrey S. Albert、David Aharony、Donald Andisik、Herbert Barthlow、Peter R. Bernstein、Russell A. Bialecki、Robert Dedinas、Bruce T. Dembofsky、Daniel Hill、Karin Kirkland、Gerard M. Koether、Benedict J. Kosmider、Cyrus Ohnmacht、William Palmer、William Potts、William Rumsey、Lihong Shen、Ashok Shenvi、Scott Sherwood、Paul J. Warwick、Keith Russell

  DOI：10.1021/jm020094i

  日期：2002.8.1

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.